RxDoctor Payments Data

Eric Snyder, MD

Ophthalmology · Holland, MINPI 1013930718

Payments from drug & device makers

$3,065in general payments, 2019–2025

Across 53 payments — averaging $57.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Microsurgical Technology, Inc.$2K
  • Lensar, Inc.$261
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$211
  • Rxsight Inc$163
  • Galderma Laboratories, L.p.$150
  • Regeneron Healthcare Solutions, Inc.$87
  • plus $493 from 13 others

What the payments were for

  • Speaking & faculty fees$1766%
  • Food & beverage$1,18939%
  • Charitable contribution$1,70055%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,065 in reported general payments places this provider in the 70th percentile of 674 ophthalmology providers in Michigan.

See all ophthalmology providers in Michigan

Medicare billing

Part B allowed, 2024
$158,164
Medicare patients
326
Services billed
1,552

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine23$36,547
RocklatanNetarsudil Mesylat/Latanoprost26$14,531
Latanoprost535$11,752
Prednisolone Acetate168$8,033
Timolol Maleate238$7,280
LumiganBimatoprost12$6,689
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat240$6,136
SimbrinzaBrinzolamide/Brimonidine Tart14$4,754
Brinzolamide13$3,976
Travoprost15$3,316
Difluprednate38$3,170
Bromfenac Sodium15$2,774
Tobramycin-DexamethasoneTobramycin/Dexamethasone41$2,352
Fluorometholone27$2,221
ValacyclovirValacyclovir Hcl31$1,898

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$84$43,23635 claims
Aerie Pharmaceuticals, Inc.Rocklatan$53$14,53126 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 674 ophthalmology providers in Michigan.

Other ophthalmology in Holland

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →